These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 24946123)

  • 1. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder.
    Xie F; Despiegel N; Danchenko N; Hansen K
    Int J Psychiatry Clin Pract; 2009; 13(1):59-69. PubMed ID: 24946123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway.
    François C; Toumi M; Aakhus AM; Hansen K
    Eur J Health Econ; 2003; 4(1):12-9. PubMed ID: 15609164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
    Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
    Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram.
    Lançon C; Verpillat P; Annemans L; Despiegel N; François C
    Int J Psychiatry Clin Pract; 2007; 11(1):44-52. PubMed ID: 24941275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.
    Ramsberg J; Asseburg C; Henriksson M
    PLoS One; 2012; 7(8):e42003. PubMed ID: 22876296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR.
    Eckert L; Falissard B
    Curr Med Res Opin; 2006 Nov; 22(11):2313-21. PubMed ID: 17076991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.
    Lam RW; Annemans L
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):559-76. PubMed ID: 20528319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
    Montgomery SA; Huusom AK; Bothmer J
    Neuropsychobiology; 2004; 50(1):57-64. PubMed ID: 15179022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis Cipriani].
    Gaillard R
    Encephale; 2009 Oct; 35(5):499-504. PubMed ID: 19853726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine.
    Chang JS; Ha K; Yoon IY; Yoo CS; Yi SH; Her JY; Ha TH; Park T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):136-42. PubMed ID: 22699029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS; Reines EH; Guiton C; Weiller E
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram for the treatment of major depression and anxiety disorders.
    Höschl C; Svestka J
    Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.